MRUS News and Press, Merus N.V. From 09/07/22

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecifi...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., P...

Merus press release ( NASDAQ: MRUS ): Q2 GAAP EPS of -$0.13 beats by $0.49 . Revenue of $12.68M (+2.4% Y/Y) beats by $2.23M . For further details see: Merus GAAP EPS of -$0.13 beats by $0.49, revenue of $12.68M beats by $2.23M

The shares of Dutch biotech Merus N.V. ( NASDAQ: MRUS ) added ~8% on Tuesday after Stifel initiated its coverage on the stock with a Buy recommendation as the analysts weighed in on the potential of thee of the company’s bispecific antibody candidates. Bispecific ...

We conclude our roundtable series with Biotech and Healthcare coverage. Seven of our Marketplace contributors give their analysis and share one top idea. Look for more roundtables and analysis this summer from our community of 180+ Marketpalce services. ~ By Tim Murphy, Ma...

Shares have risen by 40% since my 2020 ROTY update, but have lost a third of their value in 2022. I provide a recap of our thesis on this promising platform technology play in the oncology space. Data for Zeno in NRG1+ cancers at ASCO impressed with consistent ORR and clinical ben...

34% overall response rate in 79 evaluable patients with measurable disease 9.1 months median duration of response Tumor reduction in 70% of patients Zeno observed to be very well-tolerated Potential new standard of care for patients with NRG1+ cancer Investor call to d...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 03, 2022 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced that Bill Lundber...

Gainers: Avadel Pharmaceuticals (AVDL) +123%. SIGA Technologies (SIGA) +40%. Concert Pharmaceuticals (CNCE) +30%. Farfetch (FTCH) +25%. Allarity Therapeutics (ALLR) +25%. Merus N.V. (MRUS) +23%. Tenon Medical (TNON) +22%. Arcturus Therapeutics Holdings (ARCT) +19%. Red Rob...

- Robust 34% overall response rate and 9.1 months median duration of response across multiple NRG1+ tumor types - Zenocutuzumab observed to be well-tolerated - Oral presentation with additional patient data at ASCO on June 5, 2022, 9:45 -11:15 a.m. CT - Investor call to discus...